BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky, David S Jayabalan, Paul J Christos, Jessica R Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N Pearse, Faiza Zafar, Karen Pekle, April Larow, Richard Lent, Tomer Mark, Hearn J Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael W Schuster, Susan Mathew, John P Leonard, Madhu Mazumdar, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky, David S Jayabalan, Paul J Christos, Jessica R Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N Pearse, Faiza Zafar, Karen Pekle, April Larow, Richard Lent, Tomer Mark, Hearn J Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael W Schuster, Susan Mathew, John P Leonard, Madhu Mazumdar, Selina Chen-Kiang, Morton Coleman
Abstract
This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma. Patients received BiRD in 28-day cycles. Dexamethasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1 to 21. Objective response was defined by standard criteria (ie, decrease in serum monoclonal protein [M-protein] by at least 50%, and a decrease in urine M-protein by at least 90%). Of the 72 patients enrolled, 65 had an objective response (90.3%). A combined stringent and conventional complete response rate of 38.9% was achieved, and 73.6% of the patients achieved at least a 90% decrease in M-protein levels. This regimen did not interfere with hematopoietic stem-cell harvest. Fifty-two patients who did not go on to receive transplants received continued therapy (complete response, 37%; very good partial response, 33%). The major adverse events were thromboembolic events, corticosteroid-related morbidity, and cytopenias. BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203.
Source: PubMed